Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Gemcitabine 113130-nm albumin-bound paclitaxel 64Albumin-Bound Paclitaxel 43Fluorouracil 37pembrolizumab 35Magnetic Resonance Spectroscopy 35Irinotecan 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 22Cyclophosphamide 21Nivolumab 18Cisplatin 17fludarabine 16Radiosurgery 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11Carboplatin 11Blood Specimen Collection 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Biopsy, Needle × 1 year × Clear all
NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡